More than 1 in 3 parents reported that their child has dealt with dental problems linked to a lack of routine oral hygiene, ...
The U.S. Food and Drug Administration has approved a nose spray to help treat depression, Johnson & Johnson announced Tuesday ...
The Central Intelligence Agency with a "low confidence" has changed its stance and concluded that it's likely the COVI-19 ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The company reported revenue of $22.5 billion and adjusted earnings of $2.04 per share, compared to the consensus estimates ...
The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
NEW YORK, Jan. 24, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up ...
The FDA approves Spravato, a nasal spray derived from Ketamine, to help some people treat depression. Dr. Bill Hartman from UW Health shares more.
The Sackler family, owners of Purdue Pharma, reached a $7.4 billion settlement to resolve mass opioid litigation. The Department of Justice filed a civil lawsuit against Walgreens over allegations it ...
Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.